Rxsight Inc's Customers Performance

Name: Rxsight Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

RXST

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


RXST's Source of Revenues		During the corresponding time, Rxsight Inc recorded a revenue increase by 1.66 % year on year, sequentially revenue grew by 10.63 %. While revenue at the Rxsight Inc 's corporate clients • List of RXST Customers

for the same period Rxsight Inc recorded revenue increase by 1.66 % year on year, sequentially revenue grew by 10.63 %.

• List of RXST Customers

Rxsight Inc's Business Units


Product	172.29 %	of total Revenue
License and Collaboration Revenue	19.26 %	of total Revenue
LDD	10.94 %	of total Revenue
Rxlal	152.73 %	of total Revenue
Service Warranty Service Contracts And Accessories	8.62 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Rxsight Inc's Comment on Sales, Marketing and Customers

News about Rxsight Inc Contracts

RxSight Under the Lens A Class Action Call to Investors,

Investors on Alert: Class Action Lawsuit Looms Over RxSight, Inc. The financial landscape can be perilous, and for investors of RxSight, Inc. (NASDAQ: RXST), those turbulent waters are presently more daunting. Pomerantz LLP, a firm renowned for protecting shareholder rights, has sounded an alarm for such investors. A class action lawsuit has been filed against RxSight, a company renowned for its advanced optical technology. This legal action signals not merely a potential turning point for the company, but also serves as a poignant reminder of the risks incumbent in investment portfolios. RxSight and the Legal Imbroglio The centerpiece of this narrative is RxSight, Inc., a company that has largely built its ...

“RxSight Showcases Innovation in Customized Vision with the Launch of its Revolutionary Light Adjustable Lens+

RxSight, Inc., an industry-leading ophthalmic medical device firm committed to providing patients with customized vision after cataract surgery, announced the commercial availability of its most revolutionary product yet, the Light Adjustable Lens+ (LAL+). This announcement, made on April 04, 2024, emphasizes the company s relentless commitment to pioneering innovative solutions that transform eye care standards.The Aliso Viejo, California-headquartered company, known for its groundbreaking lens technology, will now offer another valuable addition to the Light Adjustable Lens platform; the LAL+ alongside the classic LAL. Both the lenses represent the advanced approach of treating post-cataract surgery vision...

RXST's Stock Performance relative to it's Customers

RXST's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Rxsight Inc	241.89	127.18	-46.64	461
SUBTOTAL	0.00	0.00	0.00	-

Sources: Rxsight Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Rxsight Inc’s corporate clients.
For your research, we’ve provided 9 tables on Rxsight Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.